Azithromycin mass treatment for trachoma control: risk factors for non-participation of children in two treatment rounds.
Persistent non-participation of children in mass drug administration (MDAs) for trachoma may reduce program impact. Risk factors that identify families where participation is a problem or program characteristics that foster non-participation are poorly understood. We examined risk factors for househ...
Saved in:
Main Authors: | Elizabeth N Ssemanda (Author), Joshua Levens (Author), Harran Mkocha (Author), Beatriz Munoz (Author), Sheila K West (Author) |
---|---|
Format: | Book |
Published: |
Public Library of Science (PLoS),
2012-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mass treatment with azithromycin for trachoma control: participation clusters in households.
by: Elizabeth N Ssemanda, et al.
Published: (2010) -
A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma.
by: Sheila K West, et al.
Published: (2013) -
Household willingness to pay for azithromycin treatment for trachoma control in the United Republic of Tanzania
by: Frick Kevin D., et al.
Published: (2003) -
Non-participation during azithromycin mass treatment for trachoma in The Gambia: heterogeneity and risk factors.
by: Tansy Edwards, et al.
Published: (2014) -
Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia.
by: Emma M Harding-Esch, et al.
Published: (2013)